PATENT CLAIM ANALYSIS

Application Number: 16134757
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["435", "006120"]

Abstract:
The present invention is related to novel methods for categorizing and treating a population of subjects that are at risk for increased pulmonary exacerbation and disease progression.

Claim (Index 21):
A method of determining pulmonary disease progression severity in a subject having cystic fibrosis and treating the subject, wherein the subject has experienced a pulmonary exacerbation, the method comprising:\n a. obtaining a whole blood sample from the subject at the time of pulmonary exacerbation; b. detecting the mRNA expression level of CD64; c. determining the severity of the pulmonary disease progress in the subject by calculating a disease risk score of mild, moderate or severe pulmonary disease progression based on the subject's mRNA expression level of CD64 from step (b) at the time of pulmonary exacerbation, wherein the subject's calculated disease risk score correlates to the risk score for mild, moderate or severe pulmonary disease progression at exacerbation; and d. treating the subject with treatments effective for treating mild, moderate or severe pulmonary disease progression.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.07692
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14665331', '15282827', '13328886', '12401381', '14799918']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6278510929174356
- 35 USC 102 Novelty (BERT): 0.5984197896640042
- Combined Prediction Score: 0.6249079625920925
- Mean Citation Score: 356.655034
- Max Citation Score: 535.08014
- Similarity Product: 483.4802870884752

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test